CD95 in cancer: tool or target?

Trauth, 1989, Monoclonal antibody-mediated tumor regression by induction of apoptosis, Science, 245, 301, 10.1126/science.2787530 Itoh, 1991, The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis, Cell, 66, 233, 10.1016/0092-8674(91)90614-5 Oehm, 1992, Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen, J. Biol. Chem., 267, 10709, 10.1016/S0021-9258(19)50076-X Scott, 2009, The Fas–FADD death domain complex structure unravels signalling by receptor clustering, Nature, 457, 1019, 10.1038/nature07606 Schleich, 2012, Stoichiometry of the CD95 death-inducing signaling complex: experimental and modeling evidence for a death effector domain chain model, Mol. Cell, 47, 306, 10.1016/j.molcel.2012.05.006 Dickens, 2012, A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death, Mol. Cell, 47, 291, 10.1016/j.molcel.2012.05.004 Kischkel, 1995, Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor, EMBO J., 14, 5579, 10.1002/j.1460-2075.1995.tb00245.x Oberst, 2011, Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis, Nature, 471, 363, 10.1038/nature09852 Kaiser, 2011, RIP3 mediates the embryonic lethality of caspase-8-deficient mice, Nature, 471, 368, 10.1038/nature09857 Zhang, 2011, Functional complementation between FADD and RIP1 in embryos and lymphocytes, Nature, 471, 373, 10.1038/nature09878 Barnhart, 2004, CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells, EMBO J., 23, 3175, 10.1038/sj.emboj.7600325 Chen, 2010, CD95 promotes tumour growth, Nature, 465, 492, 10.1038/nature09075 Cursi, 2006, Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression, EMBO J., 25, 1895, 10.1038/sj.emboj.7601085 Barbero, 2009, Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis, Cancer Res., 69, 3755, 10.1158/0008-5472.CAN-08-3937 Finlay, 2009, Critical role for caspase-8 in epidermal growth factor signaling, Cancer Res., 69, 5023, 10.1158/0008-5472.CAN-08-3731 Senft, 2007, Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility, Cancer Res., 67, 11505, 10.1158/0008-5472.CAN-07-5755 Kleber, 2008, Yes and PI3K bind CD95 to signal invasion of glioblastoma, Cancer Cell, 13, 235, 10.1016/j.ccr.2008.02.003 Steller, 2011, The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion, EMBO Rep., 12, 931, 10.1038/embor.2011.129 Letellier, 2010, CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site, Immunity, 32, 240, 10.1016/j.immuni.2010.01.011 Hoogwater, 2010, Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells, Gastroenterology, 138, 2357, 10.1053/j.gastro.2010.02.046 Reinehr, 2008, CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells, Gastroenterology, 134, 1494, 10.1053/j.gastro.2008.02.021 Reinehr, 2004, The Src family kinase Yes triggers hyperosmotic activation of the epidermal growth factor receptor and CD95, J. Biol. Chem., 279, 23977, 10.1074/jbc.M401519200 Bivona, 2011, FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR, Nature, 471, 523, 10.1038/nature09870 Stommel, 2007, Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies, Science, 318, 287, 10.1126/science.1142946 Wilson, 2012, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, 487, 505, 10.1038/nature11249 Ivaska, 2011, Cooperation between integrins and growth factor receptors in signaling and endocytosis, Annu. Rev. Cell Dev. Biol., 27, 291, 10.1146/annurev-cellbio-092910-154017 Watanabe-Fukunaga, 1992, Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis, Nature, 356, 314, 10.1038/356314a0 Roths, 1984, A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice, J. Exp. Med., 159, 1, 10.1084/jem.159.1.1 Matsuzawa, 1990, A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse, J. Exp. Med., 171, 519, 10.1084/jem.171.2.519 Lynch, 1994, The mouse Fas-ligand gene is mutated in g/cl mice and is part of a TNF family gene cluster, Immunity, 1, 131, 10.1016/1074-7613(94)90106-6 Adachi, 1995, Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver, Nat. Genet., 11, 294, 10.1038/ng1195-294 Karray, 2004, Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele, J. Immunol., 172, 2118, 10.4049/jimmunol.172.4.2118 Hao, 2004, T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis, J. Exp. Med., 199, 1355, 10.1084/jem.20032196 Akiyama, 2012, Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis, Cell Stem Cell, 10, 544, 10.1016/j.stem.2012.03.007 Chen, 1998, Regulation of the proinflammatory effects of Fas ligand (CD95L), Science, 282, 1714, 10.1126/science.282.5394.1714 Kang, 1997, Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction, Nat. Med., 3, 738, 10.1038/nm0797-738 Demjen, 2004, Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury, Nat. Med., 10, 389, 10.1038/nm1007 Newell, 2000, Fas engagement accelerates liver regeneration after partial hepatectomy, Nat. Med., 6, 920, 10.1038/78688 Badorff, 2002, Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload, J. Clin. Invest., 109, 373, 10.1172/JCI13779 Corsini, 2009, The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair, Cell Stem Cell, 5, 178, 10.1016/j.stem.2009.05.004 O’Reilly, 2009, Membrane-bound Fas ligand only is essential for Fas-induced apoptosis, Nature, 461, 659, 10.1038/nature08402 James, 2012, Biophysical mechanism of T-cell receptor triggering in a reconstituted system, Nature, 487, 64, 10.1038/nature11220 Lee, 2003, Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer, Apoptosis, 8, 151, 10.1023/A:1022918625509 Peter, 2007, The CD95 receptor: apoptosis revisited, Cell, 129, 447, 10.1016/j.cell.2007.04.031 Li, 2009, Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver, Gastroenterology, 137, 934, 10.1053/j.gastro.2009.06.004 Nijkamp, 2010, CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation, J. Hepatol., 53, 1069, 10.1016/j.jhep.2010.04.040 Kataoka, 2000, The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways, Curr. Biol., 10, 640, 10.1016/S0960-9822(00)00512-1 Nakamoto, 2002, Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-Fas ligand antibody therapy, J. Exp. Med., 196, 1105, 10.1084/jem.20020633 Ogasawara, 1993, Lethal effect of the anti-Fas antibody in mice, Nature, 364, 806, 10.1038/364806a0 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat. Med., 6, 443, 10.1038/74704 Xu, 2003, Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics, J. Immunol., 171, 562, 10.4049/jimmunol.171.2.562 Holler, 2003, Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex, Mol. Cell. Biol., 23, 1428, 10.1128/MCB.23.4.1428-1440.2003 Eisele, 2011, APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo, Neuro Oncol., 13, 155, 10.1093/neuonc/noq176 Verbrugge, 2009, Combining radiotherapy with APO010 in cancer treatment, Clin. Cancer Res., 15, 2031, 10.1158/1078-0432.CCR-08-2125 Tuettenberg, 2012, Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients, Int. Immunopharmacol., 13, 93, 10.1016/j.intimp.2012.03.004 Bendszus, 2012, A phase II, randomized, open-label, multicenter study of weekly APG101 plus reirradiation versus reirradiation in the treatment of patients with recurrent glioblastoma, J. Clin. Oncol. (Meeting Abstracts), 30